NeuroSolutions appoints Sigma Aldrich for scale-up

By Helen Schuller
Friday, 26 August, 2005

NeuroSolutions, the UK based subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has identified and selected Sigma Aldrich to provide scale-up and manufacturing services in relation to its lead pain drug candidate, NSL-043, which is due to enter a phase I clinical trial later this year.

NSL-043 has previously been developed by a Japanese company as an antirheumatic drug which progressed to complete a phase III clinical trial, passing all toxicology screens and demonstrating it was suitable for oral use, however the development was halted at this stage due to a lack of efficacy. NeuroSolutions has since reprofiled the drug candidate and undertaken extensive pre-clinical tests to demonstrate NSL-043 is potentially effective in the treatment of neuropathic pain prior to commencing the planned phase I clinical trial.

Sigma Aldrich chemists will utilise previously documented process development procedures for the synthesis of NSL-043 and determine the most efficient process for producing sufficient quantities for the commencement of a phase I clinical trial and additional trials planned for 2006.

"We reviewed a number of UK companies because we wanted to make sure we were hands on -- the lead candidate will be manufactured in the UK by Sigma Aldrich," said NeuroDiscovery chairman David McAuliffe.

"We are going to start phase I clinical trials later this year and phase II next year and plan scale up to be completed in the next six to eight weeks. It is a well know synthesis route and there shouldn't be too many complications in production," said McAuliffe.

Related News

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd